All studies
Endocrinology · Claims · US

Ray 2026

Type 2 diabetes

ITTSuperiorityAcademia2/5 disclosures
Comparisons
3
In the analysis
3
all comparisons pooled
Target trials
1
Emulations reported
3
2 treatments

Comparisons

3 shown
Randomized trialEmulation
Outcome & target trialTrial vs emulationOn a shared scaleAgreement
Time to HbA1c >= 7.0%
vs GRADE·HR·Efficacy
0.870.79–0.96
0.730.68–0.78
no overlapPartial alignment-2.89 SE apart
Time to HbA1c >= 7.0%
vs GRADE·HR·Efficacy
1.271.14–1.39
1.131.06–1.20
overlapPartial alignment-1.96 SE apart
Time to HbA1c >= 7.0%
vs GRADE·HR·Efficacy
0.690.63–0.76
0.650.60–0.70
overlapPartial alignment-0.96 SE apart

Design and methods

Estimand
ITT
Design hypothesis
Superiority
Matching / weighting
Matching weights
Analysis method
Weighted Cox proportional hazards model
Missing data
Complete case
Covariates adjusted
87
DAG
No
QBA
No

Data and sample

Data type
Claims
Data sources
1
Geography
US
Eligible sample
8092
Treated
GLP-1RA 2006; DPP-4i 2006
Control
SU 2015
Emulations
3
Treatments compared
2

Transparency

2/5
Protocol
No pre-registration
Preprint
No preprint
Data availability
Unavailable
Code availability
Unavailable
Conflicts of interest
Declared: None
Funding
Declared: Public
Funders
Grant DB-2020C2-20326 and public research support

The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.

Provenance

Review key
2026_Ray_GRADE
DOI
10.1007/s11606-026-10170-7
Affiliations
University of Maryland and collaborating US academic institutions
Sector
Academia
Target trials (study level)
GRADE
Registration
NCT01794143